Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

BACKGROUND: The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or in...

Full description

Saved in:
Bibliographic Details
Published in:BMC Neurol
Main Authors: Calkwood, Jonathan, Cree, Bruce, Crayton, Heidi, Kantor, Daniel, Steingo, Brian, Barbato, Luigi, Hashmonay, Ron, Agashivala, Neetu, McCague, Kevin, Tenenbaum, Nadia, Edwards, Keith
Format: Artigo
Language:Inglês
Published: BioMed Central 2014
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4253981/
https://ncbi.nlm.nih.gov/pubmed/25424122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-014-0220-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items